NASDAQ:PDEX

Pro-Dex - PDEX Stock Forecast, Price & News

$16.90

+0.22 (+1.32%)

(As of 12/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $16.66
▼
$17.24
50-Day Range: $15.62
▼
$19.93
52-Week Range: $12.40
▼
$26.50

Volume: 8,456 shs
Average Volume: 8,180 shs
Market Capitalization: $60.50 million

P/E Ratio: 16.25
Dividend Yield: N/A
Price Target: $30.00

Pro-Dex MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 77.5% Upside
$30.00 Price Target
Short Interest: Healthy
0.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

863rd out of 1,033 stocks

Surgical & Medical Instruments Industry

88th out of 104 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Pro-Dex has a forecasted upside of 77.5% from its current price of $16.90.
Amount of Analyst Coverage
Pro-Dex has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.40% of the float of Pro-Dex has been sold short.
Short Interest Ratio / Days to Cover
Pro-Dex has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pro-Dex has recently decreased by 14.78%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Pro-Dex does not currently pay a dividend.
Dividend Growth
Pro-Dex does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PDEX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Pro-Dex this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pro-Dex insiders have not sold or bought any company stock.
Percentage Held by Insiders
42.60% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.69% of the stock of Pro-Dex is held by institutions.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Pro-Dex is 16.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.92.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pro-Dex is 16.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 154.72.
Price to Book Value per Share Ratio
Pro-Dex has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pro-Dex (NASDAQ:PDEX) Stock

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.

Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Stock News Headlines

December 2, 2022 | americanbankingnews.com

Analyzing NEXGEL (NASDAQ:NXGL) and Pro-Dex (NASDAQ:PDEX)

November 30, 2022 | americanbankingnews.com

Pro-Dex (NASDAQ:PDEX) Coverage Initiated by Analysts at StockNews.com

November 25, 2022 | msn.com

Pro-Dex Earnings Perspective: Return On Invested Capital

November 23, 2022 | finance.yahoo.com

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pro-Dex, Inc. (NASDAQ:PDEX)?

November 9, 2022 | finance.yahoo.com

Pro-Dex First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

November 4, 2022 | finance.yahoo.com

Pro-Dex, Inc. Announces Fiscal 2023 First Quarter Results

October 22, 2022 | finance.yahoo.com

Quite a few insiders invested in Pro-Dex, Inc. (NASDAQ:PDEX) last year which is positive news for shareholders

October 17, 2022 | nasdaq.com

Pro-Dex (NASDAQ:PDEX) May Have Issues Allocating Its Capital

September 29, 2022 | finance.yahoo.com

Pro-Dex, Inc. Discusses Record-Breaking 4th Quarter Results and Year-Over-Year Growth with The Stock Day Podcast

September 26, 2022 | seekingalpha.com

Pro-Dex: Growth Trends In Earnings, Return On Investment Contracting

September 20, 2022 | finance.yahoo.com

Some Investors May Be Worried About Pro-Dex's (NASDAQ:PDEX) Returns On Capital

August 25, 2022 | finance.yahoo.com

Pro-Dex, Inc. Announces Fiscal 2022 Fourth Quarter And Full-Year Results

August 6, 2022 | reuters.com

Pro-Dex Inc

July 31, 2022 | nasdaq.com

Here's Why Pro-Dex (NASDAQ:PDEX) Has A Meaningful Debt Burden

July 14, 2022 | finance.yahoo.com

Pro-Dex (NASDAQ:PDEX) shareholders have earned a 21% CAGR over the last five years

June 14, 2022 | finance.yahoo.com

Pro-Dex, Inc. (NASDAQ:PDEX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

June 6, 2022 | finance.yahoo.com

Pro-Dex, Inc. Discusses 2022 Goals and Third Quarter Results with The Stock Day Podcast

May 15, 2022 | finance.yahoo.com

A number of insiders bought Pro-Dex, Inc. (NASDAQ:PDEX) stock last year, which is great news for shareholders

May 12, 2022 | seekingalpha.com

PDEX and DPSI among mid-day movers

May 5, 2022 | finance.yahoo.com

Pro-Dex, Inc. Announces Fiscal 2022 Third Quarter and Nine-Month Results

April 13, 2022 | finance.yahoo.com

Pro-Dex's (NASDAQ:PDEX) Returns On Capital Are Heading Higher

March 6, 2022 | finance.yahoo.com

What Is Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Doing?

February 24, 2022 | finance.yahoo.com

Pro-Dex, Inc. Discusses 2nd Quarter Sales and New Product Development with The Stock Day Podcast

February 4, 2022 | finance.yahoo.com

Pro-Dex (NASDAQ:PDEX) shareholders have earned a 36% CAGR over the last five years

February 3, 2022 | finance.yahoo.com

Pro-Dex, Inc. Announces Fiscal 2022 Second Quarter and Six-Month Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Company Calendar

Last Earnings: 11/15/2021
Today: 12/05/2022
Next Earnings (Estimated): 2/02/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PDEX
CUSIP: N/A
CIK: 788920
Web: www.pro-dex.com
Phone: (949) 769-3200
Fax: 949-769-3281
Employees: 117
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.00
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +77.5%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.04
Trailing P/E Ratio: 16.25
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $3.86 million
Net Margins: 8.97%
Pretax Margin: 10.73%
Return on Equity: 16.75%
Return on Assets: 8.53%

Debt

Debt-to-Equity Ratio: 0.41
Current Ratio: 2.73
Quick Ratio: 1.39

Sales & Book Value

Annual Sales: $42.04 million
Price / Sales: 1.44
Cash Flow: $1.31 per share
Price / Cash Flow: 12.91
Book Value: $6.54 per share
Price / Book: 2.58

Miscellaneous

Outstanding Shares: 3,580,000
Free Float: 2,055,000
Market Cap: $60.50 million
Optionable: Not Optionable
Beta: 0.91

Key Executives

Mr. Richard Lee Van Kirk Jr. (Age 61)
CEO & Director
Comp: $416.38k

Ms. Alisha K. Charlton (Age 52)
CFO & Corp. Sec.
Comp: $300.22k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PDEX Stock - Frequently Asked Questions

What is Pro-Dex's stock price forecast for 2023?: 0 Wall Street research analysts have issued 1 year price objectives for Pro-Dex's shares. Their PDEX share price forecasts range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 77.5% from the stock's current price.
View analysts price targets for PDEX or view top-rated stocks among Wall Street analysts.
How have PDEX shares performed in 2022?: Pro-Dex's stock was trading at $23.21 at the beginning of 2022. Since then, PDEX shares have decreased by 27.2% and is now trading at $16.90.
View the best growth stocks for 2022 here.
When is Pro-Dex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our PDEX earnings forecast.
How were Pro-Dex's earnings last quarter?: Pro-Dex, Inc. (NASDAQ:PDEX) released its quarterly earnings results on Monday, November, 15th. The medical instruments supplier reported $0.28 earnings per share for the quarter, hitting analysts' consensus estimates of $0.28. The medical instruments supplier had revenue of $9.99 million for the quarter. Pro-Dex had a net margin of 8.97% and a trailing twelve-month return on equity of 16.75%.
What is Michael J. Berthelot's approval rating as Pro-Dex's CEO?: 3 employees have rated Pro-Dex Chief Executive Officer Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among the company's employees.
What other stocks do shareholders of Pro-Dex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH).

What is Pro-Dex's stock symbol?: Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
Who are Pro-Dex's major shareholders?: Pro-Dex's stock is owned by many different retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.62%), LSV Asset Management (0.91%) and Tower Research Capital LLC TRC (0.08%). Insiders that own company stock include Alisha Charlton, Katrina Marie Kramer Philp, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III.
View institutional ownership trends.
How do I buy shares of Pro-Dex?: Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pro-Dex's stock price today?: One share of PDEX stock can currently be purchased for approximately $16.90.
How much money does Pro-Dex make?: Pro-Dex (NASDAQ:PDEX) has a market capitalization of $60.50 million and generates $42.04 million in revenue each year. The medical instruments supplier earns $3.86 million in net income (profit) each year or $1.04 on an earnings per share basis.
How many employees does Pro-Dex have?: The company employs 117 workers across the globe.
How can I contact Pro-Dex?: Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for the company is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281.

This page (NASDAQ:PDEX) was last updated on 12/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial